Decheng Capital Management IV Increases Stake in Equillium, Inc. to 6.7%

Decheng Capital Management IV (Cayman), LLC and associated reporting persons filed a Schedule 13G/A on May 15, 2026, regarding their holdings in Equillium, Inc. (EQ). As of the event date on March 31, 2026, Decheng Capital Management IV reported beneficial ownership of 4,271,423 shares of common stock, representing a 6.7% ownership stake. This position includes 3,285,710 shares and warrants for 985,713 shares held directly by Decheng Capital Global Life Sciences Fund IV, L.P. Additional reporting persons include Decheng Capital Global Healthcare Fund (Master), LP, which holds 1,461,598 shares (including warrants), and Dr. Xiangmin Cui, who oversees the entities and is deemed to have shared voting and investment power over a total of 5,733,021 shares, or 8.9% of the issuer. The filing indicates an increase in holdings compared to previous reports of zero ownership. The reporting persons certified that the shares were acquired for investment purposes and not to influence or change the control of the issuer.